SUMMARY mTORC1 is a signal integrator and master regulator of cellular anabolic processes linked to cell growth and survival. Here, we demonstrate that mTORC1 promotes lipid biogenesis via SRPK2, a key regulator of RNA-binding SR proteins. mTORC1-activated S6K1 phosphorylates SRPK2 at Ser494, which primes Ser497 phosphorylation by CK1. These phosphorylation events promote SRPK2 nuclear translocation and phosphorylation of SR proteins. Genome-wide transcriptome analysis reveals that lipid biosynthetic enzymes are among the downstream targets of mTORC1-SRPK2 signaling. Mechanistically, SRPK2 promotes SR protein binding to U1-70K to induce splicing of lipogenic pre-mRNAs. Inhibition of this signaling pathway leads to intron retention of lipogenic genes, which triggers nonsense-mediated mRNA decay. Genetic or pharmacological inhibition of SRPK2 blunts de novo lipid synthesis, thereby suppressing cell growth. These results thus reveal a novel role of mTORC1-SRPK2 signaling in post-transcriptional regulation of lipid metabolism and demonstrate that SRPK2 is a potential therapeutic target for mTORC1-driven metabolic disorders.
INTRODUCTION
A hallmark of living organisms is their ability to sense and couple various environmental cues to their growth. The mechanistic target of rapamycin complex 1 (mTORC1) integrates signals from growth factors, nutrients, and energy status, serving as a molecular rheostat, to regulate a wide range of anabolic and catabolic processes (Dibble and Manning, 2013; Gomes and Blenis, 2015; Saxton and Sabatini, 2017; Shimobayashi and Hall, 2014) . mTORC1 is an atypical serine/threonine protein kinase that promotes cell growth through phosphorylation of multiple proteins including the ribosomal S6 kinase 1 (S6K1) and eIF4E-binding protein 1 (4E-BP1) (Ma and Blenis, 2009) . Growth factors such as insulin activate PI3K-AKT signaling, thereby inhibiting the tumor suppressor tuberous sclerosis complex (TSC) 1/2, a negative regulator of mTORC1 (Manning and Toker, 2017; Shimobayashi and Hall, 2014) . Loss-of-function mutations in TSC1/2 lead to constitutive activation of mTORC1, which causes genetic tumor syndromes TSC and lymphangioleiomyomatosis (LAM) (Crino et al., 2006) . Hyperactivation of mTORC1 by oncogenic PI3K-AKT and RAS-ERK pathways is also commonly observed in numerous cancers (Menon and Manning, 2008) . Therefore, it is of great therapeutic importance to better understand how mTORC1 is able to control diverse cellular processes through regulation of newly discovered downstream targets.
Cancer cells regulate synthesis of macro-molecules to support sustained proliferation (DeBerardinis and Thompson, 2012 ; Vander Heiden et al., 2009) . De novo lipid synthesis, for instance, provides fatty acids and cholesterol for expanding cell and organelle membranes (Gonzalez Herrera et al., 2015; Menendez and Lupu, 2007) . This process begins with the production of acetyl coenzyme A (acetyl-CoA) from citrate or acetate by ATP citrate lyase (ACLY) or acyl-CoA synthetase short-chain (ACSS) family members, respectively. Fatty acid synthase (FASN) then catalyzes synthesis of fatty acids using acetyl-CoA and malonyl-CoA, which is produced from acetyl-CoA by acetyl-CoA carboxylase (ACC). The resulting palmitate is then utilized to generate a number of products, such as longer fatty acids via elongation, unsaturated fatty acids via stearoyl-CoA desaturase 1 (SCD1), phospholipids, and signaling lipids. For cholesterol biosynthesis, hydroxymethylglutaryl-CoA synthase (HMGCS) catalyzes condensation of acetyl-CoA with acetoacetyl-CoA to generate HMG-CoA, which is converted to mevalonic acid by HMG-CoA reductase (HMGCR). This is then followed by multiple enzymatic reactions including those mediated by mevalonate diphosphate decarboxylase (MVD) and farnesyl diphosphate farnesyltransferase 1 (FDFT1). These key enzymes are often overexpressed in cancers (Currie et al., 2013; Menendez and Lupu, 2007) . Thus, understanding the pertinent regulatory mechanisms holds promise for revealing potential therapeutic targets. One such regulator is the sterol regulatory element binding protein (SREBP) family of transcription factors, SREBP1 and 2. SREBPs are produced as inactive precursors bound to the endoplasmic reticulum membrane. Upon cellular lipid depletion, SREBPs are proteolytically processed to their active forms, translocate to the nucleus, and induce transcription of target genes (Horton et al., 2002) . mTORC1 increases expression of lipogenic enzymes through SREBP activation, by both inactivating its negative regulators and increasing its expression level (Dü vel et al., 2010; Li et al., 2010; Owen et al., 2012; Peterson et al., 2011; Han et al., 2015) . However, little is known about the post-transcriptional regulation of lipogenic enzyme expression or whether the pro-lipogenic activity of mTORC1 extends to these events.
Cells employ a wide variety of post-transcriptional mechanisms for fine-tuning mRNAs and generating proteomic diversity, such as splicing, capping, polyadenylation, methylation, nuclear export, and stability (Fabian et al., 2010; Gilbert et al., 2016; Moore and Proudfoot, 2009; Park et al., 2005) . These processes are regulated in part by various RNA-binding proteins, including serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) (Chen and Manley, 2009) . SR proteins are encoded by the serine and arginine rich splicing factor (SRSF) gene family and composed of RNA recognition motifs (RRM) and arginine/serine (RS)-repeat domains. They catalyze mRNA processing by directly binding to exons in pre-mRNA and recruiting proteins such as small nuclear ribonucleoproteins (SNRNPs) (Fu and Ares, 2014; Lee and Rio, 2015) . The activity of SR proteins can be regulated via phosphorylation of the RS domain by SR protein kinases (SRPKs), which alters SR protein conformation, subcellular localization, and/or its interaction with other proteins (Ghosh and Adams, 2011) .
Here, we reveal a previously unknown layer of mTORC1-dependent regulation of lipid metabolism that utilizes a new mTORC1-regulated effector kinase, SRPK2. Mechanistically, SRPK2 controls expression of lipogenic enzymes by inducing efficient splicing of their mRNAs rather than by affecting the synthesis of transcripts. Our findings uncover a mechanism by which nutrients and growth factors fine tune the regulation of splicing. Furthermore, our study highlights SRPK2 as a potential therapeutic target for mTORC1-driven diseases such as cancer and metabolic disorders.
RESULTS

Identification of SRPK2 as a Novel Downstream Target of mTORC1 Signaling
We previously performed a stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative phospho-proteomics screen of mTORC1 signaling and identified SRPK2 as a putative downstream target ( Figure 1A ) (Yu et al., 2011) . The putative phosphorylation sites in SRPK2, Ser494 and Ser497, are located in the linker region that splits the kinase domain and are evolutionarily conserved among vertebrates ( Figure 1B ). These phosphorylation sites were also detected in mTORC1 phospho-proteomics studies carried out by other groups (Hsu et al., 2011; Robitaille et al., 2013) . To verify that mTORC1 regulates phosphorylation of SRPK2, we performed SDS-PAGE mobility shift assays. Upon insulin treatment to activate mTORC1 in HEK293E cells, the mobility of SRPK2 was dramatically decreased in a time-dependent manner, and the effect of insulin was completely blocked by rapamycin pre-treatment ( Figure 1C ), indicating the presence of insulin-regulated and rapamycin-sensitive phosphorylation(s). To further characterize Ser494 and Ser497 phosphorylation, we generated phosphospecific antibodies. Consistent with the gel mobility changes, insulin induced SRPK2 phosphorylation at Ser494 and Ser497, which was abolished by rapamycin treatment or SRPK2 knockdown ( Figure 1D ). We also tested SPRK2 phosphorylation in cell lines that display constitutively active mTORC1 activity. In these cells, SRPK2 was phosphorylated even in the absence of growth factors, which was blunted by mTORC1 inhibition with rapamycin (Figures 1E and 1F) . Together, these results indicate that SRPK2 is phosphorylated at Ser494 and Ser497 in an mTORC1-dependent manner.
S6K1 Directly Phosphorylates SRPK2 at Ser494, which Primes for Ser497 Phosphorylation by CK1
We next sought to identify the kinase(s) that directly phosphorylates SRPK2. The Ser494 residue of SRPK2 is surrounded by a phosphorylation motif (RXRXX[S/T]) recognized by the basophilic protein kinase A, G, and C (AGC) kinase family (Pearce et al., 2010a) (Figure 2A ). Since S6K1 is an AGC kinase directly activated by mTORC1, we examined whether S6K1 phosphorylates SRPK2 at Ser494. Efficient knockdown of S6K1 inhibited insulininduced phosphorylation of SRPK2 at Ser494 ( Figure 2B ). In addition, the S6K1 inhibitor PF4708671 (Pearce et al., 2010b) reduced SRPK2 phosphorylation as robustly as rapamycin, Torin1 (mTOR active site inhibitor) (Thoreen et al., 2009) , and MK2206 (AKT inhibitor) (Lindsley, 2010) (Figure 2C ). Expression of an activated, rapamycin-resistant form of S6K1 (F5A-T389E-R3A) (Schalm and Blenis, 2002) induced SRPK2 phosphorylation even in the presence of rapamycin ( Figure 2D ). To further determine whether S6K1 directly phosphorylates SRPK2, we performed in vitro kinase assay. S6K1 immunoprecipitated from insulin treated cells, but not from rapamycin pre-treated cells, directly phosphorylated recombinant SRPK2 proteins ( Figure 2E ). Mutation of SRPK2-Ser494 to alanine (S494A) substantially abrogated SRPK2 phosphorylation by S6K1 ( Figure 2E ), demonstrating that Ser494 is the major S6K1 phosphorylation site in SRPK2. Collectively, these results indicate that S6K1 directly phosphorylates SRPK2 downstream of mTORC1 signaling.
Interestingly, we noted that Ser497 on SRPK2 is also phosphorylated in an mTORC1 and S6K1-dependent manner, and this phosphorylation is tightly correlated with phosphorylation of Ser494 (Figures 1 and 2) . However, the phosphorylation motif surrounding Ser497 does not match the consensus AGC kinase substrate motif (Figure 2A ). We therefore wanted to determine whether the phosphorylation at Ser494 primed Ser497 for phosphorylation. We knocked down endogenous SRPK2 with a 3 0 UTR-targeting short-hairpin RNA (shRNA), followed by expression of SRPK2 wild-type (SRPK2-WT) or non-phosphorylatable mutants (SRPK2-S494A or S497A) in TSC2-deficient cells (Figures 2F and 2G) . Mutation of Ser494 to alanine dramatically inhibited phosphorylation of not only Ser494 but also Ser497, whereas mutation of Ser497 to alanine affected only its own phosphorylation ( Figure 2G ). These data indicate that Ser494 phosphorylation is crucial for Ser497 phosphorylation. Bioinformatics analysis revealed that Ser497 becomes a casein kinase 1 (CK1) target site when Ser494 is phosphorylated (pS/TXX[S/T]) ( Figure 2H ) (Flotow et al., 1990) . Consistent with the primed substrate recognition mechanism, CK1 directly phosphorylated the recombinant SRPK2 proteins containing a phospho-mimetic mutation at Ser494 (S494D) ( Figure 2I ). This phosphorylation efficiency was decreased in the non-phosphorylated S494A mutant, and even more decreased in S494A/ S497A mutant ( Figure 2I ), suggesting that Ser497 is the primary CK1 target residue. Taken together, these results demonstrate that CK1 functions as the SRPK2-Ser497 kinase following the priming phosphorylation of Ser494 by S6K1. 2012). We therefore determined whether insulin and mTORC1 signaling regulates nuclear-cytoplasmic shuttling of SRPK2. Endogenous SRPK2 was predominantly localized in the cytoplasm in serum-starved HEK293E cells ( Figure 3A ). Insulin treatment induced nuclear accumulation of SRPK2, which was blocked by Torin1 pre-treatment ( Figure 3A ). Consistent with the nuclear accumulation of SRPK2, phosphorylation of SR proteins was increased by insulin ( Figure 3B ). Notably, in cell lines with high basal mTORC1 activity, SRPK2 predominantly localized to the nucleus ( Figures 3C-3E ). Inhibition of mTORC1 activity by rapamycin or Torin1 ( Figures 3C and 3E ) or by TSC2 reconstitution ( Figure 3D ) induced cytoplasmic retention of SRPK2. These results show that insulin-mTORC1 signaling promotes nuclear localization of SRPK2. We next investigated whether phosphorylation of SRPK2 at Ser494 and Ser497 is important for nuclear trafficking of SRPK2. In TSC2-deficient cells lacking endogenous SRPK2 by knockdown ( Figure 2F ), exogenously expressed SRPK2-WT (C) Immunoblot analysis of HEK293E cells. Cells were serum starved overnight and treated with the indicated small molecule inhibitors for 30 min, followed by insulin (100 nM) treatment for 2 hr. Rapamycin (100 nM), Torin1 (250 nM), MK2206 (10 mM), and PF4708671 (10 mM) were used. (D) Immunoblot analysis of HEK293E cells transfected with HA-S6K1-CA (constitutively active S6K1) or vector. Cells were serum starved overnight and treated with insulin (100 nM) for 2 hr with or without rapamycin (20 nM) pre-treatment for 30 min. (E) HEK293E cells transfected with HA-S6K1 were serum starved overnight and treated with insulin (100 nM) for 2 hr with or without rapamycin (20 nM) pre-treatment for 30 min. In vitro kinase assay was performed using HA-S6K1 immunoprecipitated (IP) from these cells. Recombinant GST-SRPK2-wild-type (WT) and S494A proteins were used as substrates. WCL, whole-cell lysates. was localized in the nucleus ( Figures 3F and 3G ), whereas significantly less was observed to localize in the nucleus following rapamycin treatment ( Figures 3F and 3G ). In contrast, unlike SRPK2-WT, which accumulated in the nucleus of TSC2-deficient cells due to its constitutive phosphorylation, the non-phosphorylatable SRPK2-S494A, S497A, and S494A/S497A mutants were distributed to the cytoplasm and this localization was not further changed by rapamycin ( Figures 3F, 3G , S1A, and S1B).
Using in silico search, we found that SRPK2 contains a putative Importin alpha/beta-dependent nuclear-localization signal (NLS) near the Ser494 and Ser497 phosphorylation sites ( Figure S1C ) (Kosugi et al., 2009) . Indeed, knockdown of Importin-beta prevented nuclear accumulation of SRPK2 (Figures S1D and S1E), suggesting that SRPK2 phosphorylation is important for Importin alpha/beta-dependent NLS recognition and nuclear translocation (Nardozzi et al., 2010) . Consistently, SRPK2-WT led to increased phosphorylation of SR proteins in TSC2-deficient cells ( Figures 3H and 3I ), whereas the kinase dead (K110M) or non-phosphorylatable (S494A) SRPK2 mutant had no effect ( Figures 3H and 3I) . Collectively, these results demonstrate that mTORC1-dependent SRPK2 phosphorylation induces SRPK2 nuclear localization and SR protein phosphorylation.
SRPK2 Regulates Expression of Lipid Biosynthetic
Enzymes SR proteins are implicated in many aspects of mRNA biogenesis such as transcription, splicing, export, translation, and stability (Chen and Manley, 2009; Fu and Ares, 2014) . We therefore wanted to determine whether mTORC1-mediated regulation of SRPK2 alters RNA metabolism. To this end, we conducted whole-transcriptome microarray analyses of gene expression and exon/ intron utilization on TSC2-deficient cells after rapamycin treatment or SRPK2 knockdown ( Figure S2A Figure 4A ). Strikingly, among these 21 commonly decreased genes in both conditions, several encode enzymes crucial for lipid metabolism (highlighted in blue, Figure 4B ) including those involved in de novo lipid synthesis such as ACLY, ACSS2, HMGCS1, MVD, and FDFT1 (highlighted in red, Figure 4C ). Real-time qPCR confirmed that the mRNA levels of these genes were significantly suppressed by mTORC1 inhibition using rapamycin or Torin1 treatment as well as by SRPK2 knockdown ( Figure 4D ). Furthermore, expression of FASN and SCD1, key enzymes for fatty acid synthesis previously linked to mTORC1 signaling ( Figure 4C ) (Dü vel et al., 2010; Peterson et al., 2011) , was also substantially decreased by SRPK2 knockdown ( Figure S2D ). Consistent with the decreased mRNA expression, protein levels of these enzymes were dramatically reduced by rapamycin as well as by SRPK2 knockdown and knockout ( Figures 4E and 4F ). Overexpression of wild-type SRPK2, but not the non-phosphorylatable SRPK2 mutant, restored the expression of lipogenic enzymes in SRPK2 knockdown cells ( Figure 4G ). Collectively, these results show that mTORC1-SRPK2 signaling regulates a broad gene expression program linked to lipid biosynthesis.
Lipogenic genes are transcriptionally regulated by SREBP1/2 transcription factors, which are regulated by mTORC1 (Horton et al., 2002; Caron et al., 2015) . Thus, we determined whether SRPK2 induces lipid biosynthetic enzymes through SREBP1/2 in TSC2-deficient cells. In these cells, mTORC1 signaling is constitutively active independent of growth factors (Dü vel et al., 2010; Zhang et al., 2014) . Analysis of promoter regions covering 1 kb upstream of lipogenic genes (including SREBPbinding sites) showed that lipid deprivation by serum removal dramatically increased their promoter activity, which was suppressed by SREBP1/2 knockdown ( Figure 5A ) (Horton et al., 2002) . Surprisingly, despite remarkable reduction of mRNA and protein levels of lipogenic enzymes by SRPK2 knockdown (Figure 4) , we found no reduction in the promoter activity of these genes following SRPK2 knockdown ( Figure 5B ). Indeed, SCD1 and ACSS2 displayed increased promoter activity, which may reflect a feedback loop ( Figure 5B ). In addition, the cleavage and nuclear translocation of SREBP1, which are key steps of SREBP1 activation (Horton et al., 2002) , were induced by lipid deprivation but not affected by SRPK2 deficiency ( Figure 5C ). Together, these results strongly suggest that SRPK2 controls expression of target genes by post-transcriptional mechanisms.
SRPK2 Increases mRNA Stability of Lipogenic Genes by Promoting Efficient Intron Splicing
We therefore investigated whether SRPK2 regulates expression of target genes via mRNA stability. We treated cells with actinomycin D to block transcription and measured the time-dependent turnover of lipogenic mRNAs (Tani and Akimitsu, 2012) . The mRNA stability of FDFT1, SCD1, ACLY, ACSS2, HMGCS1, and MVD was markedly decreased by SRPK2 knockdown as well as by rapamycin treatment ( Figure 5D ). However, rapamycin or SRPK2 knockdown did not affect the mRNA stability of phosphofructokinase, platelet (PFKP) or ribose 5-phosphate isomerase A (RPIA) ( Figure 5D ), known mTORC1 transcriptional target genes in glycolysis and pentose phosphate pathway, respectively (Dü vel et al., 2010) . Importantly, the transcriptome array analysis showed that lipogenic genes including ACSS2, FDFT1, HMGCS1, and MVD retained introns upon rapamycin treatment or SRPK2 knockdown (Figures S3A and S3B), indicating a reduced efficiency of intron splicing. In contrast, PFKP or RPIA did not exhibit consistent intron retention under these same conditions. Introns often contain stop codons, causing ribosome stalling and recruitment of the nonsense-mediated decay (NMD) machinery, and thereby triggering degradation of abnormal mRNAs (Chang et al., 2007; Isken and Maquat, 2008) . The retained introns in these genes contained stop codons ( Figure S3A ), suggesting that NMD could contribute to the mRNA instability by SRPK2 deficiency. To test this possibility, we inhibited NMD by knocking down a key NMD factor, up-frameshift 1 (UPF1) (Chang et al., 2007) , which restored the mRNA levels of lipogenic genes in SRPK2 knockout cells to the levels in control cells (Figures 5E and S3C) . Thus, NMD, at least in part, contributes to SRPK2-controlled regulation of mRNA stability.
Since SRPK2 downstream targets, the SR proteins, are RNA binding proteins, we determined whether SR proteins are involved in the regulation of lipogenic gene expression. Knockdown of some (SRSF1/2/3) but not all SR proteins resulted in a dramatic reduction in mRNA levels of lipogenic genes (Figures 5F and S3D), suggesting that a subset of SR proteins mediate the SRPK2-dependent regulation of lipogenic gene expression. In silico analysis predicted several SRSF1/2/3 binding sites in lipogenic genes (Table S1 ). Thus, we performed RNA-immunoprecipitation assay of SRSF1 and found that lipogenic transcripts bind to SRSF1 (Figures S3E and S3F) . SR proteins do not contain enzymatic activities but rather participate in the recruitment of spliceosome complex proteins (e.g., small nuclear ribonucleoproteins) to induce splicing (Kohtz et al., 1994; Lee and Rio, 2015) . To test whether mTORC1-SRPK2 signaling controls the interaction of SR proteins with spliceosomal proteins, we performed a proteomics-based interactome analysis for SRSF1 under vehicle-versus Torin1-treated conditions (Figure S4A) . In Torin1-treated cells, we found reduced binding of SRSF1 with a small nuclear ribonucleoprotein U1 subunit 70 (SNRNP70/U1-70k) ( Figure S4B ; Table S2 ), a spliceosomal component required for splice site recognition and subsequent assembly of the spliceosome (Lee and Rio, 2015) . Co-immunoprecipitation and immunoblotting confirmed that Torin1 significantly inhibited the binding of SRSF1 with U1-70k, which was accompanied with reduced SRSF1 phosphorylation ( Figure 5G ). Although not previously known to be regulated by the mTORC1 pathway, phosphorylation of SRSF1 by SRPK2 was shown to promote its interaction with U1-70k, thereby enhancing splicing of pre-mRNAs (Cho et al., 2011; Kohtz et al., 1994; Wang et al., 1998) . Thus, our findings are consistent with these observations and further suggest a role for mTORC1 in regulating this MVD  ACSS2  ZBED6CL  ACLY  FABP3  THRSP  HSPA5  AKR1C2  ADAMTS12  TNFRSF9  FDFT1  MTCH2  MLKL  HSD11B1  OAS1  TMEM138  CHN1 interaction. Finally, knockdown of U1-70k increased intron retention and decreased expression of several lipogenic genes, but not PFKP or RPIA (Figures 5H and S3G) . Together, these results suggest that mTORC1 signaling promotes the interaction of SR proteins with the spliceosomal protein U1-70k to induce efficient splicing of lipogenic pre-mRNAs.
SRPK2 Is Necessary for De Novo Synthesis of Cellular Fatty Acids and Cholesterol
We next examined whether the altered expression of lipid biosynthetic enzymes affects cellular lipid metabolism. To measure de novo lipid synthesis, we cultured TSC2-deficient cells in serum-free conditions with 14 C-labeled acetate and quantified Tables S1 and S2. the amount of newly synthesized fatty acids and cholesterol by high-performance liquid chromatography (HPLC) ( Figure 6A ). Knockdown of SREBP1/2, as a positive control, decreased fatty acid and cholesterol synthesis ( Figures S5A-S5C ) (Dü vel et al., 2010; Ricoult et al., 2016) . Both stable and transient knockdown of SRPK2 significantly reduced fatty acid and cholesterol synthesis ( Figures 6A-6D ) as did treatment with rapamycin or Torin1 ( Figures 6E and 6F ) (Dü vel et al., 2010; Ricoult et al., 2016) . We also measured de novo fatty acid synthesis in cells cultured with 13 C-glucose by liquid chromatography-mass spectrometry (LC-MS) (Kamphorst et al., 2013) . This approach allows us to determine production of different fatty acid products. In serum-free conditions, we observed only a small effect on 13 C incorporation into the saturated fatty acids palmitate or stearate ( Figures 6G and 6H ). We did, however, observe a pronounced reduction in the synthesis of oleate, which is made from stearate by desaturation (Figures 6G and 6H) . Under more physiological conditions, including the presence of serum, we observed a more substantial reduction in synthesis of both saturated and especially unsaturated fatty acids from glucose ( Figures 6H-6J ). Altogether, these results support the important role of mTORC1-SRPK2 signaling in regulating de novo lipid synthesis.
Inhibition of SRPK2 Blunts Cell Growth upon Lipid Starvation
Consistent with the reduced lipogenic potential, SRPK2-knocked down TSC2-deficient cells showed retarded cell proliferation ( Figures 7A and 7B ), which was more prominent when the growth was made more dependent on de novo lipid synthesis upon removal of lipids from the media ( Figures  7A and 7B) . Importantly, supplementation with lipoproteins (composed of cholesterol and fatty acids) or oleate (fatty acid) partially restored the growth of SRPK2-deficient cells (Figures 7C and 7D) , indicating that the growth defect by SRPK2 knockdown is in part due to an insufficient supply of lipids. To further validate the roles of SRPK2 on lipogenesis and cell growth, we employed an SRPK1/2 inhibitor, SRPIN340 (Fukuhara et al., 2006) . SRPIN340 treatment reduced expression of lipogenic enzymes in a dose-dependent manner ( Figures  S6A-S6D ). This inhibitory effect of SRPIN340 is likely due to SRPK2 suppression because SRPIN340 did not further reduce lipogenic gene expression in SRPK2 knockout cells ( Figure 7E ). In addition, knockdown of SRPK1, a paralog of SRPK2 (Wang et al., 1998) , alone did not significantly affect lipogenic enzyme levels except SCD1 ( Figure 7F ). SRPIN340 treatment also dramatically suppressed de novo synthesis of fatty acids (Figure S6E ) and cell growth in tumor cell lines with high mTORC1 activity ( Figures 7G and S6F) . To test the in vivo relevance of these findings in the context of cancer, we conducted xenograft growth studies with cell lines with high mTORC1 activity. Strikingly, both genetic (knockdown or knockout) and pharmacological inhibition of SRPK2 inhibited tumor growth across each of these multiple cancer cell line xenograft models ( Figures 7H-7K, S6G , and S6H). Thus, these results further demonstrate that SRPK2 is a crucial downstream mediator for mTORC1-dependent lipogenesis, a process that contributes substantially to tumor growth.
DISCUSSION
Here, we report an unexpected link between the mTORC1 and SRPK2 signaling pathways. This signaling axis seems to be a key post-transcriptional regulator of lipid biosynthetic enzymes to support cell proliferation. Together with the known stimulatory function of mTORC1 on SREBP-dependent transcription, our study reveals that mTORC1 signaling utilizes both transcriptional and post-transcriptional mechanisms to amplify cellular lipid biogenesis ( Figure S7 ).
Our findings indicate that the functional consequence of SRPK2 phosphorylation by mTORC1/S6K1 is its translocation from cytoplasm to nucleus (Figure 3) . The downstream substrates of SRPKs, SR proteins, are involved in RNA metabolism and predominantly locate in the nucleus (Fu and Ares, 2014; Ghosh and Adams, 2011) . Accordingly, SRPK2 nuclear localization is a critical node by which upstream signals (e.g., mTORC1/ S6K1) regulate SRPK2 signaling. Previously, AKT was shown to induce SRPK2 phosphorylation at Thr492 to enhance its binding to 14-3-3 proteins (which often retain associated proteins in the cytoplasm) (Jang et al., 2009; Rittinger et al., 1999) . However, AKT activation paradoxically resulted in SRPK2 nuclear accumulation (Jang et al., 2009 ). Since AKT activates mTORC1/S6K1 signaling, SRPK2 nuclear localization downstream of AKT is consistent with our results (Figure 3) . It is possible that AKT temporally retains SRPK2 in the cytoplasm via 14-3-3 proteins, but S6K1 activation downstream of AKT subsequently induces SRPK2 nuclear translocation not only via SRPK2 phosphorylation, but possibly also via AKT inhibition through the well-established negative feedback mechanisms regulated by mTORC1 and S6K1 (Mendoza et al., 2011) .
Another interesting aspect of SRPK2 phosphorylation is that the Ser494 phosphorylation by mTORC1/S6K1 induces subsequent Ser497 phosphorylation by CK1 (Figure 2 ). Although CK1 is constitutively active, its action on substrates is usually contingent upon priming phosphorylation by a different kinase (Flotow et al., 1990; Cheong and Virshup, 2011) . For example, phosphorylation of DEPTOR on Ser293 and Ser299 by mTORC1 is followed by CK1, which creates a binding site on DEPTOR for bTrCP ubiquitin ligase (Duan et al., 2011; Gao et al., 2011) . The amino acids around the SRPK2 phosphorylation sites are an Importin-alpha/beta-dependent NLS sequence ( Figure S1C ) (Kosugi et al., 2009) , whose interaction with substrates is known to be enhanced by substrate phosphorylation around the NLS (Nardozzi et al., 2010) . Thus, sequential phosphorylation by mTORC1/S6K1 and CK1 promotes efficient nuclear accumulation of SRPK2 and downstream signaling. It will be of great interest to investigate the kinetics of SRPK2 nuclear localization and how this results in additional nuclear phosphorylation events and mTORC1-dependent interaction with other proteins.
To support increased proliferation rates, cancer cells rewire their metabolism to meet the high demand for biosynthesis of macromolecules. Targeting metabolism has recently emerged as a new therapeutic strategy for cancer treatment (DeBerardinis and Thompson, 2012; Vander Heiden et al., 2009) . Expression of enzymes for lipid biosynthesis such as ACLY, ACC, FASN, and SCD1 is often elevated in tumors (Currie et al., 2013; Menendez and Lupu, 2007) . Indeed, inhibition of these enzymes has been reported in certain cases to selectively kill cancer cells and retard tumor growth in xenograft models (Currie et al., 2013; Menendez and Lupu, 2007) . SRPK2 is overexpressed in several cancer types including lung, colon, and acute myeloid leukemia (Gout et al., 2012; Jang et al., 2008; Wang et al., 2016) . SRPK2 is a kinase and, therefore, a promising druggable target (Cohen, 2002; Fukuhara et al., 2006; Zhang et al., 2009) . It is thus plausible to develop compounds that specifically inhibit SRPK2 for clinical use. Our results showed that SRPK2 inhibition with lipid deprivation inhibits cancer cell proliferation (Figure 7) . Therefore, combination therapies using specific SRPK2 inhibitors and lipid uptake blockers such as CD36 antibodies (Pascual et al., 2017; Selwan et al., 2016) would also be a promising regimen for treatment of cancers with high dependency on mTORC1 signaling and lipid metabolism. 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines RT4, MCF7, DLD1, A549, and mAb104 cells were obtained from ATCC. HEK293T cells were obtained from GenHunter. Human renal angiomyolipoma-derived LAM 621-101 (TSC2À/À) cell line immortalized by HPV E6/E7 and hTERT was described before (Yu et al., 2004) . Eker rat uterine leiomyoma-derived ELT3 (Tsc2À/À) cell line was provided by Cheryl Walker (Texas A & M University) (Howe et al., 1995) and used to generate ELT3-luciferase cell line stably expressing luciferase as previously described (Yu et al., 2009) . Tsc2À/À mouse embryonic fibroblasts (MEFs) were provided by David Kwiatkowski (Harvard Medical School) (Zhang et al., 2003) . Cells were grown in the following media at 37 C with 5% CO 2 unless otherwise stated. HEK293E, HEK293T, RT4, and Tsc2À/À MEFs were cultured in DMEM with 10% FBS. MCF7, DLD1, and A549 cells were cultured in RPMI with 10% FBS. mAb104 cells were cultured in Iscove's modified Dulbecco's medium (IMDM) with 20% FBS. LAM 621-101 and ELT3 cells were cultured in IIA complete media (DMEM/F12, 10% FBS, 1 nM triiodothyronine, 10 mU/mL vasopressin, 200 nM hydrocortisone, 50 nM sodium selenite, 10 nM cholesterol, 20 ng/mL EGF, 25 mg/mL insulin, 10 mg/mL transferrin, and 1.6 mM ferrous sulfate) (Yu et al., 2004; Yu et al., 2009 ).
Mice
All animal work was performed in accordance with protocols approved by the University of Cincinnati Standing Committees on Animals. 6-8 week-old female nude CD-1 mice (Charles River), NOD/SCID-gamma mice (Jackson Lab), and CB17-scid mice (Taconic) were used.
Microbe strains E. coli BL21 (New England Biolabs) was grown at 28 C in 2x YTA medium for protein purification.
METHODS DETAILS
Antibodies and small molecule inhibitors Cell Signaling Technology custom developed the pSRPK2(S494), pSRPK2(S497), and pSRPK2(S494/S497) antibodies for this study. Antibodies were obtained from following sources: SRPK1 and SRPK2 from BD Biosciences; ACLY, FASN, SCD1, S6, pS6(S235/ S236), pS6(S240/S244), S6K1, pS6K1(T389), TSC2, and V5 from Cell Signaling Technology; ACSS2 and GAPDH from Sigma-Aldrich; FDFT1 from Abcam; SRSF1, ACTIN, GST, LAMIN A/C, and SREBP1 from Santa Cruz; HA from Covance; U1-70k from Synaptic Systems. Monoclonal antibody for the phosphorylated SR proteins was generated from the mAb104 hybridoma cell line (ATCC) ( Figures  3B and 3H ) or purchased from invitrogen (mAB1H4) ( Figure 5G ). Reagents were obtained from following sources: Insulin, rapamycin, PF4708671, and actinomycin D from Sigma-Aldrich; Torin1 from Tocris Bioscience; rapamycin from Calbiochem; MK2206 from Cayman Chemical; SRPIN340 from Selleck Chemicals and Milstein Chemistry Core Facility (Weill Cornell Medicine).
Gene expression analysis and measurement of mRNA stability RNA was isolated using RNeasy Mini Kit (QIAGEN) or PureLink RNA Mini kit (Ambion) and treated with DNase I (QIAGEN or SigmaAldrich) according to the manufacturers' instructions. After reverse-transcription of 500-1,000 ng RNA (iScript cDNA synthesis kit, Bio-rad), the resulting cDNA was diluted in nuclease-free water (1:5) followed by quantitative real-time PCR (qPCR) using QuantStudio 6 Flex (Applied Biosystems). Gene expression levels were normalized to the expression level of the housekeeping genes ACTIN, TATA-binding protein (TBP) or Peptidylpropyl isomerase B (PPIB). To measure mRNA stability, transcription was blocked by actinomycin D (5 mg/ml) treatment for 0, 2, and 4 hr. Reverse-transcription was performed using the same volume of RNA for all time points and the mRNA levels were measured by qPCR (Tani and Akimitsu, 2012) .
Human whole transcriptome microarray Total RNA was isolated using RNeasy Mini Kit (QIAGEN) and treated with DNase I (QIAGEN). Microarray was performed by the Translational Genomics Core at Partners HealthCare Personalized Medicine (MA, USA) according to the protocol from Affymetrix. Briefly, 100 ng total RNA was used to synthesize biotinylated cDNA using GeneChip whole transcript (WT) plus reagent kit. 5.5 mg cDNA was fragmented and labeled by terminal deoxynucleotidyl transferase (GeneChip WT terminal labeling kit). The resulting cDNA was hybridized to the Human Transcriptome 2.0 Array at 45 C for 16 hr. Array chips were washed and stained using GeneChip fluidics station 450, and scanned using GeneChip Scanner 3000 7G. Data were analyzed by Expression console (Affymetrix) and Transcriptome analysis console software (Affymetrix) according to the manufacturer's instruction.
HPLC analysis of de novo lipid synthesis
Cells in a 6-well plate were cultured in serum-free DMEM (5.5 mM glucose) overnight or for 24 hr (for drug treatment conditions), and labeled with [1-14 C]-acetate (2-8 mCi/well) (Perkin Elmer) for the last 6 hr. The cells were washed three times with PBS and lysed by methanol containing the internal standard 13(S)-hydroxyoctadecadienoic acid [13(S)-HODE] (2 mg/well) (Cayman Chemicals). Cell lysates were collected with a cell scraper and transferred to a glass vial. Lipids were extracted by addition of chloroform and water (methanol:chroloform:water = 1:1:0.9, by volume). After centrifugation (800 rpm, 10 min), the lower phase was transferred to a new vial and evaporated under a stream of N 2 . The lipids were then dissolved in methanol (1 mL), hydrolyzed by 0.5 mL of 1 N NaOH at room temperature for 2 hr, and re-extracted by addition of chloroform (2 mL), 1N HCl (0.5 mL), and water (2 mL). After centrifugation, the lower phase was transferred to a new vial. Samples were evaporated under a stream of N 2 and dissolved in 0.2 mL of hexane: isopropanol:acetic acid (100:3:0.02, by volume) for HPLC analysis. Samples were analyzed using an Agilent Zorbax Silica column (5 mm, 4.6x250 mm) with isocratic elution of hexane:isopropanol:acetic acid (100:3:0.02, by volume) at a flow rate of 1 mL/min over 12 min, on an Agilent 1260 Infinity binary system with a Diode array detector coupled to a Perkin-Elmer Radiometric 150TR detector (Zheng et al., 2011) . The retention time of fatty acids and cholesterol was determined by standard lipids. Peak areas of radiolabeled fatty acids and cholesterol were integrated (Agilent OpenLAB CDS ChemStation) and normalized to that of 13(S)-HODE and cell number.
LC-MS analysis of saponified fatty acids
Extraction and LC-MS analysis of fatty acids were performed as previously described (Kamphorst et al., 2013) . Briefly, cells in a 60-mm plate were supplemented with 17.5 mM [U-13 C]-glucose (Cambridge Isotope Laboratories) in DMEM/F12 with or without 10% dialyzed FBS (Sigma-Aldrich) or lipoprotein-deficient serum (Intracel or Alfa Aesar) for 48 hr. The cells were washed three times with PBS and lysed with 2 mL of 0.3 M KOH in 90% methanol. Cell lysates were collected with a cell scraper and transferred to a glass vial. Lipids were hydrolyzed at 80 C for 1 hr and formic acid (0.2 mL) was added for neutralization. The lipids were extracted twice by adding 2 mL of hexane and transferring the top layer to a new vial. Samples were evaporated under a stream of N 2 and dissolved in 0.1 mL of isopropanol:methanol (1:1, v/v) solution for LC-MS analysis (Stand-alone Orbitrap, Thermo Fisher). De novo synthesized fatty acids were determined based on the sum of all forms containing four or more labeled carbon atoms (fatty acids containing 2-labeled carbon atoms are made from elongation not de novo synthesis). Data analysis with MAVEN software and natural isotope correction were performed as previously described (Kamphorst et al., 2013) .
Cell proliferation assay
Cells seeded on a 12-well plate (LAM 621-101, 2 3 10 3 cells; MCF7 and RT4, 2 3 10 4 cells) were grown in the media (LAM 621-101, DMEM/F12; MCF7, RPMI; RT4, DMEM) with 10% FBS or LPDS for 8 days. Lipoprotein (25 mg/ml), oleic acid-albumin (50 mM), or fatty acid-free albumin (25 mM) was supplemented to the media. Cristal violet staining was performed to visualize cells. Briefly, cells were fixed with 4% methanol-free formaldehyde (Polysciences) in PBS for 30 min and rinsed with PBS. The cells were incubated with 0.1% crystal violet solution (Sigma-Aldrich) for 30 min at room temperature. After rinsing five times with water, the plate was air-dried and scanned. Quantification was performed by densitometry analysis of images using Adobe Photoshop.
In vivo xenograft tumor assay All animal work was performed in accordance with protocols approved by the University of Cincinnati Standing Committees on Animals. Female nude CD-1 mice (Charles River) (A549 cell line), NOD/SCID-gamma mice (Jackson Lab) (LAM 621-101 cell line), and CB17-scid mice (Taconic) (RT4 and ELT3-luciferase cell lines), 6 to 8 weeks of age, were used. 2x10 6 cells were subcutaneously inoculated into the posterior back regions of each mouse. Once the tumor is formed three to five weeks post inoculation, tumor length and width were measured using a digital caliper. Tumor volume was calculated using the formula: volume = (length 3 (width) 2 /2). For the drug treatment experiment, mice were randomized into two groups after tumor formation and treated with either vehicle control (100 mL of 1% DMSO in PBS) or SRPIN340 (100 mL of 20 mg/ml; 1% DMSO in PBS) by daily peritumoral injection as previously described (Gammons et al., 2014) . SRPIN340 was dissolved as 2 mg/ml in DMSO, and this stock solution was diluted 1:1,000 using PBS prior to inject. For the bioluminescent imaging of ELT3-luciferase tumors, luciferin (120 mg/kg, Xenogen) was intraperitoneally injected into the mouse 10 min prior to imaging. Bioluminescent signals were recorded using the Xenogen IVIS System and the total photon flux of tumors was analyzed as previously described (Yu et al., 2009) .
Mass spectrometry analysis of SRSF1 interactome HEK293E cells were transfected with empty vector (EV) or pLX304-SRSF1-V5. After 24 hr transfection, cells were treated with vehicle (DMSO) or Torin1 (250 nM) for additional 4 hr according to the three experimental conditions: EV+DMSO, SRSF1-V5+DMSO, and SRSF1-V5+Torin1. Cells were washed once with ice-cold PBS and disrupted on ice with lysis buffer (50 mM Tris-Cl buffer [pH 8], 150 mM NaCl, and 0.5% NP-40) supplemented with protease inhibitors (250 mM PMSF, 5 mg/ml pepstatin A, 10 mg/ml leupeptin, and 5 mg/ml aprotinin), phosphatase inhibitors (PhosSTOP, Roche), and RNase inhibitor (160 unit/ml). Lysates were homogenized by syringe. Cleared lysates were obtained by centrifugation at 15,000 rpm at 4 C for 30 min. For co-immunoprecipitation, lysates were incubated with anti-V5 agarose affinity gel (Sigma-Aldrich) at 4 C for 2.5 hr and washed three times with the lysis buffer. Immunoprecipitated proteins were analyzed by immunoblotting or further processed for the mass spectrometry (MS) analysis.
For MS analysis, the immunoprecipitated proteins were eluted from the beads by incubating with V5 peptide (Sigma-Aldrich) overnight at 4 C. Protein elutes were precipitated with trichloroacetic acid (TCA, 20% w/v), rinsed three times with acetone, and dried at room temperature. The pellets were re-suspended in 50 mL resuspension buffer (8 M urea, 50 mM ammonium bicarbonate, and 5 mM DTT) and subjected to reduction and alkylation reaction. Briefly, 15 mM iodoacetamide was added to each sample for 30 min in the dark at room temperature, followed by addition of another 5 mM DTT to quench the reaction. Samples were diluted to a final concentration of 1 M urea, and then subsequently digested with LysC (room temperature, overnight) and trypsin (37 C, overnight) (each at a ratio of 1:125, enzyme:protein).
Samples were then labeled using triplex reductive dimethylation (Boersema et al., 2008) . Labeling was done while the peptides were bound to the solid phase C18 resin in self-packed STAGE tip micro-columns. Stage tips were washed as previously described with methanol, acetonitrile (ACN, 70% v/v) and formic acid (FA, 1% v/v) , and finally with 1% FA. Samples were acidified by adding 100% FA to a final concentration of 2% FA before loading. After sample loading, stage tips were washed with 1% FA and phosphate/ citrate buffer (0.23 M sodium phosphate and 86.4 mM citric acid [pH 5.5]). At this point, the ''light'' solution for EV+DMSO (0.4% CH 2 O and 60 mM NaBH 3 CN)', ''medium'' solution for SRSF1-V5+DMSO (0.4% CD 2 O and 60 mM NaBH 3 CN), or ''heavy'' solution for SRSF1-V5+Torin1 (0.4% 13 CD 2 O and 60 mM NaBD 3 CN) was added twice on each stage tip to label the peptides. A final wash with 1% FA was performed prior to elution with 70% ACN and 1% FA. Samples were dried under vacuum, resuspended in 5% FA, and mixed together in equal amounts for analysis using an Orbitrap Fusion Mass Spectrometer (Thermo Fisher). Peptides were introduced into the mass spectrometer by nano-electrospray as they eluted off a self-packed 40 cm, 75 mm (ID) reverse-phase column packed with 1.8 mm, 120 Å pore size, SEPAX C18 resin. Peptides were separated with a gradient of 5%-25% buffer B (99.9% ACN, 0.1% FA) with a flow rate of 350 nl/min for 85 min. For each scan cycle, one high mass resolution full MS scan was acquired in the Orbitrap mass analyzer at a resolution of 120K, AGC value of 500,000, in a m/z scan range of 375-1,400, max acquisition time of 100 ms and up to 20 parent ions were chosen based on their intensity for collision induced dissociation (normalized collision energy = 35%) and MS/MS fragment ion scans at low mass resolution in the linear ion trap. Dynamic exclusion was enabled to exclude ions that had already been selected for MS/MS in the previous 40 s. Ions with a charge of +1 and those whose charge state could not be assigned were also excluded. All scans were collected in centroid mode. Two biological replicates for each condition were processed and analyzed. All raw mass spectral data were processed using the Maxquant analysis platform and subsequent visualization and statistical analysis was done with Perseus (Tyanova et al., 2016) . Spectra were searched using the Andromeda algorithm. Prior to run Maxquant, the following dynamic and fixed modifications were set: oxidation methionine and acetyl protein N-term (as dynamic), carbamidomethyl in cysteines (as fixed). Spectral matches were filtered to 1% false positive rate.
SILAC cell culture and mass spectrometry analysis of phosphorylated proteins Sample preparation for the stable isotope labeling with amino acids in cell culture (SILAC) experiments and LC-MS/MS analysis were previously described (Yu et al., 2011 N 4 ]-Arg) (Cambridge Isotope Laboratories) DMEM supplemented with 10% dialyzed FBS. Cells were serum starved for 17 hr and treated with vehicle or rapamycin (20 nM) for 2 hr. Cells were lysed and digested with trypsin, and the phosphopeptides were enriched by SCX-IMAC method. Samples were analyzed by LTQ-Orbitrap mass spectrometer (Thermo Fisher) as previously described (Yu et al., 2011) .
RNA-protein immunoprecipitation (RNA-IP)
RNA-protein immunoprecipitation was performed using Imprint RNA immunoprepitation (RIP) kit (Sigma-Aldrich) according to the manufacturer's protocol. Cells on a 15-cm plate were washed twice with ice-cold PBS and harvested into Eppendorf tube. Cells were collected by centrifugation at 3,000 rpm at 4 C for 5 min. Cell pellets were re-suspended with 100 mL of strong lysis buffer (RIP kit) supplemented with protease inhibitors (protease inhibitor cocktail, 1 mL) and RNase inhibitor (160 unit/mL) and incubated on ice for 15 min. Cell lysates were snap-frozen in liquid nitrogen and thawed on ice.
To prepare antibody-prebound beads, 5 mg of mouse IgG (EMD Millipore) or anti-SRSF1 antibody (Santa Cruz) was conjugated to the 50 mL protein A/G magnetic beads (Thermo Fisher). Cell lysates and the antibody-prebound beads were incubated in 1 mL RIP buffer at 4 C for 3 hr. Beads were washed and RNA was eluted by incubating with 150 mL RIP buffer containing 1% SDS and 1.2 mg/mL proteinase K (New England Biolabs) at 55 C for 30 min. The eluted RNA was further purified by phenonol/chroloform extraction and precipitated with ammonium acetate and ethanol. Input and immunoprecipitated RNAs were treated with DNase I (Sigma-Aldrich) and reverse-transcribed (iScript cDNA synthesis kit, Bio-rad), and the resulting cDNA was analyzed by qPCR as described in the Gene expression analysis section. The amount of transcripts (%) bound to the antibody was calculated: 100 X 2[ Ct(input) -Ct(IP)].
Luciferase promoter activity assay Cells plated on a 6-well plate were co-transfected with 1 mg of renillia construct containing the promoter of interested gene and 0.2 mg of control cypridina construct using FuGENE HD transfection reagent (Promega). For co-transfection of luciferase constructs with siRNA, SE. Cell Line 4D-Nucleofector X Kit and 4D-Nucleofector system (Lonza) were used. 48 hr after transfection, the activity of luciferase was measured by LightSwitch dual assay system (SwitchGear Genomics) according to the manufacturer's protocol. Renilla luciferase activity was normalized by cypridina luciferase activity.
Expression constructs and mutagenesis
For expression studies, the coding sequence of human SRPK2 (NM_001278273.1) was cloned into pKH3 vector (BclI/BamHI and MfeI/EcoRI), and the HA-SRPK2 from pKH3-SRPK2 was subcloned into pLNCX vector (NotI and SalI). To generate GST-tagged cleared by centrifugation at 12,000 g at 4 C for 10 min and incubated with 50% slurry of Glutathione Sepharose 4B (GE Healthcare Life Sciences) at 4 C for 2 hr. After rinsing three times with PBS, proteins were eluted with 1 mL elution buffer (50 mM Tris-HCl and 10 mM reduced glutathione, pH 8.0).
For S6K1 in vitro kinase assay, immunoprecipitated HA-S6K1 from HEK293E was incubated with 1 mg of GST-SRPK2 in a kinase assay buffer (25 mM Tris-HCl, [pH 7.4], 10 mM MgCl 2 , 5 mM b-glycerophosphate, 2 mM DTT, and 100 mM ATP) containing 5 mCi [g-32 P]-ATP (Perkin Elmer) at 30 C for 20 min. For CK1 in vitro kinase assay, 200 ng of GST-CK1 (EMD Millipore) was incubated with GST-SRPK2 in the kinase assay buffer containing 5 mCi [g-32 P]-ATP at 30 C for 30 min. Samples were separated by SDS-PAGE, blotted onto nitrocellulose membrane, and subjected to autoradiography.
Immunofluorescence staining Cells grown on a fibronectin and gelatin-coated glass coverslip in a 12-well plate were fixed with 4% methanol-free formaldehyde in PBS for 30 min. The cells were rinsed with PBS and permeabilized with 0.1% Triton X-100 in PBS for 10 min. Then the cells were blocked for 1 hr with the blocking buffer (50:50 mixture of 0.1% Triton X-100 buffer and LI-COR blocking buffer, LI-COR Biosciences) and incubated with anti-SRPK2 (1:100 dilution, BD Biosciences) and anti-pS6(S235/S236) (1:200 dilution, Cell Signaling Technology) antibodies in the blocking buffer overnight at 4 C. After rinsing three times with the Triton X-100 buffer, cells were incubated with the secondary antibodies conjugated with Alexa488 or with Alexa568 (1:1,000 dilution in the blocking buffer) at room temperature for 1 hr and washed three times with the Triton X-100 buffer. The cells were then incubated with 0.5 ug/mL Hoechst 33258 (Thermo Fisher) in PBS for 10 min, rinsed twice with PBS, and mounted onto the glass slides with a Dako mounting medium (Sigma-Aldrich). Images were taken using Nikon upright microscope or Zeiss laser scanning confocal microscope, and analyzed using MetaMorph software at Nikon Imaging Center (Harvard Medical School). For the quantification of cell numbers regarding nuclear-cytoplasmic localization of SRPK2, the average intensity of nuclear-SRPK2 (nucleus area is determined as overlapping with DAPI signal) was measured in control cells, and the cells containing nuclear-SRPK2 intensity above the average intensity of control were counted as nucleus.
Bioinformatics and in silico analysis
For the gene ontology (GO) enrichment analysis ( Figure S2C and Table S2D), the list of genes was uploaded to the DAVID database website (https://david.ncifcrf.gov/) for biological pathway analysis. The criteria selected for the analysis were: gene identifier (OFFICIAL_GENE_SYMBOL), background genes (whole human genome), and analytic tool (functional annotation).
For the transcription factor enrichment analysis ( Figure S2D ), the list of genes was uploaded to the web-based gene set analysis toolkit (http://www.webgestalt.org/option.php) for identification of transcription factor binding site enrichments in upstream promoter regions. The criteria selected for the analysis were: organism (hsapiens), method (overrepresentation enrichment analysis, ORA), functional database (network, Transcription_factor_target), gene ID type (genesymbol), and reference set for enrichment analysis (affy_hta_2_0).
To analyze putative SRSF1, SRSF2, and SRSF3 binding sites (Table S1 ), the mRNA sequence of the transcripts was uploaded to the web server for mapping binding sites of RNA-binding proteins (http://rbpmap.technion.ac.il) (Paz et al., 2014) . The criteria selected for the analysis were: RNA binding protein (Human/mouse motifs; SRSF1, SRSF2, and SRSF3) and Stringency level (high stringency).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data obtained from the qPCR, immunoblot, immunofluorescence staining, crystal violet staining, HPLC, and proteomics were statistically analyzed using Student's t test and the graphs show mean ± SD. Data obtained from the whole transcriptome array and tumor xenograft assays were statistically analyzed using ANOVA analysis and the graphs show mean ± SEM. Detailed methods and p value for the statistical significance are described in the figure legends and methods details.
DATA AND SOFTWARE AVAILABILITY
The whole transcriptome microarray data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GEO: GSE104335 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104335). Figure S4 . Interactome Analysis of SRSF1, Related to Figure 5 (A) Schematics of interactome analysis. HEK293E cells were transfected with empty vector or SRSF1-V5, followed by treatment with vehicle or Torin1 (250 nM) for 4 hr. SRSF1-binding proteins were co-immunoprecipitated by anti-V5 agarose beads and eluted by V5 peptides. Eluted proteins were digested with LysC and trypsin, isotopically labeled using triplex reductive dimethylation, mixed, and analyzed by mass spectrometry. (B) MS spectra of EFEVYGPIK peptide from U1-70k/SNRNP70, which was identified to interact with SRSF1 and the interaction was decreased by Torin1. mTORC1 signaling induces transcription of lipid biosynthetic enzymes through SREBP transcription factors. In addition, mTORC1 signaling phosphorylates and activates SRPK2. The activated SRPK2 promotes interaction of SR proteins with the spliceosomal protein U1-70k to induce efficient splicing of lipogenic premRNAs. Inhibition of this signaling pathway leads to substantial intron retention of these genes, which in turn triggers NMD-mediated mRNA destabilization and thereby causes decreased protein expression.
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